Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMOQDBA)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
2,2'-Pyridylisatogen tosylate; 56583-49-4; PIT; 2-(2-pyridinyl)-(3h)-indol-3-one-1-oxide 4-methylbenzenesulfonate; 4-methylbenzenesulfonic acid; 1-oxido-2-pyridin-2-ylindol-1-ium-3-one; Tocris-1682; AC1L3Y9P; AC1Q6WM2; GTPL1729; CHEMBL1364808; CTK1H0971; MolPort-023-276-189; HMS3268O03; AKOS024456745; 2-(pyridin-2-yl)-3h-indol-3-one 1-oxide 4-methylbenzenesulfonate(1:1); NCGC00025378-01; KB-221271; B6827; SR-01000597767; SR-01000597767-1; 4-methylbenzenesulfonic acid
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
